Cessation Therapeutics has received an additional grant from the US National Institutes of Health’s division National Institute on Drug Abuse (NIDA) to develop a subcutaneous formulation of the anti-fentanyl mAb (monoclonal antibody), CSX-1004 SQ.
The funding is a component of a multi-year $14.8m grant awarded to Cessation and McLean Hospital, part of Mass General Brigham.
Go deeper with GlobalData
The grant will support activities including CSX-1004 SQ’s formulation, development and manufacture, and assess its ability to reduce the impact of fentanyl in pre-clinical models of fentanyl self-administration and relapse.
Cessation used funds from a previous NIDA grant to perform IND-enabling trials of CSX-1004 infusion, an investigational product that has now advanced to Phase I studies.
Designed to work by sequestering fentanyl molecules as they enter the bloodstream, CSX-1004 is a human IgG1 mAb specifically for fentanyl and fentanyl analogues.
It helps neutralise the molecules in the blood before they reach the brain and prevents harmful effects.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThrough a range of delivery techniques, the platform can be optimised to prevent overdoses, to potentially reverse overdoses and to treat fentanyl-related opioid use disorder (OUD).
Cessation Therapeutics chief scientific officer Andy Barrett stated: “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programmes.
“This award to support a fixed-dose, subcutaneous formulation of CSX-1004 significantly catalyses our IND-enabling efforts to develop a ready-to-use formulation of CSX-1004 tailored to patients’ needs in a broad range of healthcare settings.”
